within Pharmacolibrary.Drugs.ATC.M;

model M03BA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 25.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 350 / 1000000,
    adminCount     = 1,
    Vd             = 0.000992,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01155,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Carisoprodol is a centrally acting skeletal muscle relaxant that blocks pain sensations between the nerves and the brain. It is primarily used for the short-term relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol is a controlled substance due to its potential for abuse and dependence; in many countries, its use has been reduced or discontinued. In the United States, carisoprodol remains approved for prescription use for up to two or three weeks at a time.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single oral administration.</p><h4>References</h4><ol><li><p>Bramness, JG, et al., &amp; Mørland, J (2005). The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. <i>European journal of clinical pharmacology</i> 61(7) 499–506. DOI:<a href=&quot;https://doi.org/10.1007/s00228-005-0970-1&quot;>10.1007/s00228-005-0970-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16021435/&quot;>https://pubmed.ncbi.nlm.nih.gov/16021435</a></p></li><li><p>Zhu, LL, et al., &amp; Zhou, Q (2024). Tizanidine: Advances in Pharmacology &amp; Therapeutics and Drug Formulations. <i>Journal of pain research</i> 17 1257–1271. DOI:<a href=&quot;https://doi.org/10.2147/JPR.S461032&quot;>10.2147/JPR.S461032</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38529017/&quot;>https://pubmed.ncbi.nlm.nih.gov/38529017</a></p></li><li><p>Coulter, C, et al., &amp; Moore, C (2012). Determination of carisoprodol and meprobamate in oral fluid. <i>Journal of analytical toxicology</i> 36(3) 217–220. DOI:<a href=&quot;https://doi.org/10.1093/jat/bks009&quot;>10.1093/jat/bks009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22417839/&quot;>https://pubmed.ncbi.nlm.nih.gov/22417839</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M03BA02;
